Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men? — VialBase Research
Argues bremelanotide should be considered for male sexual arousal and desire disorders
- Argues bremelanotide should be considered for male sexual arousal and desire disorders
- CNS mechanism (MC3R/MC4R) distinguishes it from PDE5 inhibitors
- Preclinical and early clinical data show efficacy in male ED
- Particularly relevant for psychogenic ED where mechanism is central, not vascular
- Potential benefit for men who do not respond to PDE5 inhibitors
Summary
Expert review by Pfaus and Balon arguing that bremelanotide should be considered for treating sexual arousal and desire disorders in men, not just women. Currently FDA-approved only for premenopausal female HSDD (Vyleesi), but the authors present evidence that the CNS mechanism (melanocortin receptor agonism) is equally relevant to male sexual dysfunction.
Key Findings
- Bremelanotide’s MC3R/MC4R mechanism acts on hypothalamic sexual desire circuits — not gender-specific
- Early clinical data in men showed improvement in erectile function, particularly psychogenic ED
- PDE5 inhibitors work peripherally on blood flow; bremelanotide works centrally on desire
- Patients who fail PDE5 inhibitor therapy may benefit from the orthogonal mechanism
- The FDA-approval gap (approved for women, not men) may be a regulatory artifact rather than scientific one
Relevance to PT-141
Extends PT-141’s clinical utility beyond its current FDA-approved indication. The argument for male use is mechanistically sound — MC3R/MC4R are expressed in the hypothalamus regardless of sex. This represents potential label expansion and reinforces PT-141’s unique position as a CNS-acting sexual health compound.
Citation
Pfaus JG, Balon R. J Clin Psychopharmacol. 2026 Apr 10. PMID: 41960633
See Also
- Parent compound: PT-141
Save 15% with code VIALBASE
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.